BACKGROUND: Dyslipidaemia is a key risk factor for atherosclerotic cardiovascular disease (ASCVD), necessitating effective statin therapy. Despite statins' proven safety and efficacy, adherence remains suboptimal, with significant gaps between clinical practice and guideline recommendations. METHODS: This retrospective cohort study analysed anonymized health administrative claims data from six employee health funds in the Czech Republic, covering approximately 40% of the insured population from January 1, 2017, to December 31, 2020. We identified statin-incident as well as prevalent cohort of patients. Adherence to statin therapy was assessed using the proportion of days covered (PDC) metric, with factors such as age, gender, sequence of use, and treatment intensity considered as modifiers. RESULTS: Among the statin-prevalent cohort (SP, n = 890,180), 83.5% achieved a PDC ≥ 50%, and 61.0% reached a PDC ≥ 80%. In the statin-incident cohort (SI, n = 287,871), a clear trend of increasing adherence with age and medication sequence was observed: in adults aged 18-39 median PDC rose from 84.1% (IQR: 57-100) in the first to 94.7% (IQR: 75.6-100) in the third sequence; in those aged 80 + median PDC rose from 95.0% (IQR: 68.9-100) in the first to 100% (IQR: 78.3-100) in the third sequence. Logistic regression identified age (OR=1.011 per year), female gender (OR=0.896), high-intensity treatment (OR=0.975), and second (OR=1.267) or later treatment sequences (OR=1.704) as significant predictors of adherence (all p < 0.001). CONCLUSION: Adherence to statin therapy improves with subsequent treatment sequences and age. These findings highlight the need for targeted interventions to enhance adherence, particularly among younger patients. The PDC metric is recommended for integration into clinical practice to monitor and improve medication adherence.

3rd Department of Medicine General University Hospital and 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Biomedical Technology Faculty of Biomedical Engineering Czech Technical University Prague Czech Republic

Department of Internal Medicine and Cardiology University Hospital Brno and Faculty of Medicine Masaryk University Brno Czech Republic

Department of Neurology International Clinical Research Center St Anne's University Hospital and Faculty of Medicine Masaryk University Brno Czech Republic

Department of Neurology Mayo Clinic Rochester Minnesota United States of America

Zobrazit více v PubMed

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. doi: 10.1093/eurheartj/ehz455 PubMed DOI

Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279–89. doi: 10.1093/eurjpc/zwaa047 PubMed DOI

Vrablik M, Seifert B, Parkhomenko A, Banach M, Jóźwiak JJ, Kiss RG, et al. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study. Atherosclerosis. 2021;334:66–75. doi: 10.1016/j.atherosclerosis.2021.08.035 PubMed DOI

Vrablík M, Šarkanová I, Breciková K, Šedová P, Šatný M, Tichopád A. Low LDL-C goal attainment in patients at very high cardiovascular risk due to lacking observance of the guidelines on dyslipidaemias. PLoS One. 2023;18(5):e0272883. doi: 10.1371/journal.pone.0272883 PubMed DOI PMC

Hope HF, Binkley GM, Fenton S, Kitas GD, Verstappen SMM, Symmons DPM. Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease. PLoS One. 2019;14(1):e0201196. doi: 10.1371/journal.pone.0201196 PubMed DOI PMC

Vonbank A, Agewall S, Kjeldsen KP, Lewis BS, Torp-Pedersen C, Ceconi C, et al. Comprehensive efforts to increase adherence to statin therapy. Eur Heart J. 2017;38(32):2473–9. doi: 10.1093/eurheartj/ehw628 PubMed DOI

Colantonio LD, Rosenson RS, Deng L, Monda KL, Dai Y, Farkouh ME, et al. Adherence to statin therapy among US adults between 2007 and 2014. J Am Heart Assoc. 2019;8(1):e010376. doi: 10.1161/JAHA.118.010376 PubMed DOI PMC

Cupido AJ, Hof MH, de Boer LM, Huijgen R, Stroes ESG, Kastelein JJP, et al. Adherence to statin treatment in patients with familial hypercholesterolemia: A dynamic prediction model. J Clin Lipidol. 2023;17(2):236–43. doi: 10.1016/j.jacl.2022.12.004 PubMed DOI

Zhao B, He X, Wu J, Yan S. Adherence to statins and its impact on clinical outcomes: a retrospective population-based study in China. BMC Cardiovasc Disord. 2020;20(1):282. doi: 10.1186/s12872-020-01566-2 PubMed DOI PMC

Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother. 2009;10(18):2973–85. doi: 10.1517/14656560903376186 PubMed DOI

Hope HF, Binkley GM, Fenton S, Kitas GD, Verstappen SMM, Symmons DPM. Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease. PLoS One. 2019;14(1):e0201196. doi: 10.1371/journal.pone.0201196 PubMed DOI PMC

Engebretsen I, Munkhaugen J, Bugge C, Halvorsen S, Ødegaard KM, Støvring H, et al. Gaps and discontinuation of statin treatment in Norway: potential for optimizing management of lipid lowering drugs. Eur Heart J Open. 2022;2(6):oeac070. doi: 10.1093/ehjopen/oeac070 PubMed DOI PMC

Merlo J, Öberg J, Khalaf K, Perez-Vicente R, Leckie G. Geographical and sociodemographic differences in statin dispensation after acute myocardial infarction in Sweden: a register-based prospective cohort study applying analysis of individual heterogeneity and discriminatory accuracy (AIHDA) for basic comparisons of healthcare quality. BMJ Open. 2023;13(9):e063117. doi: 10.1136/bmjopen-2022-063117 PubMed DOI PMC

Ma K, Ohm J, Yip Lundstrom L, Yari A, Jernberg T, Svensson P. Lower income is associated with non-persistence to statin treatment after a first myocardial infarction. European Heart J. 2023;44(Supplement_2). doi: 10.1093/eurheartj/ehad655.2473 DOI

Kirilova K, Trečiokienė I, Bratčikovienė N, Qvarnström M, Wettermark B. Persistence to statin treatment: a cohort study in Lithuania. Basic Clin Pharmacol Toxicol. 2024;135(1):43–51. doi: 10.1111/bcpt.14015 PubMed DOI

Ágh T, Garuolienė K, Granas AG, Gregório J, Aksoy N, Khanyk N, et al. Identifying and presenting key country-specific indicators related to medication adherence: a comprehensive study across European countries. Front Pharmacol. 2024;15:1390629. doi: 10.3389/fphar.2024.1390629 PubMed DOI PMC

Loucks J, Zuckerman AD, Berni A, Saulles A, Thomas G, Alonzo A. Proportion of days covered as a measure of medication adherence. Am J Health Syst Pharm. 2022;79(6):492–6. doi: 10.1093/ajhp/zxab392 PubMed DOI

Do you know the difference between these adherence measures?. Pharmacy Times. Accessed 2025 March 12. https://www.pharmacytimes.com/view/do-you-know-the-difference-between-these-adherence-measures

Huddy K, Dhesi P, Thompson PD. Do the frequencies of adverse events increase, decrease, or stay the same with long-term use of statins? Curr Atheroscler Rep. 2013;15(2):301. doi: 10.1007/s11883-012-0301-9 PubMed DOI

Rottman BM, Marcum ZA, Thorpe CT, Gellad WF. Medication adherence as a learning process: insights from cognitive psychology. Health Psychol Rev. 2017;11(1):17–32. doi: 10.1080/17437199.2016.1240624 PubMed DOI

Bytyçi I, Penson PE, Mikhailidis DP, Wong ND, Hernandez AV, Sahebkar A, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43(34):3213–23. doi: 10.1093/eurheartj/ehac015 PubMed DOI PMC

Ofori-Asenso R, Jakhu A, Zomer E, Curtis AJ, Korhonen MJ, Nelson M, et al. Adherence and persistence among statin users aged 65 years and over: a systematic review and meta-analysis. J Gerontol A Biol Sci Med Sci. 2018;73(6):813–9. doi: 10.1093/gerona/glx169 PubMed DOI

Banach M, Burchardt P, Chlebus K, Dobrowolski P, Dudek D, Dyrbuś K, et al. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci. 2021;17(6):1447–547. doi: 10.5114/aoms/141941 PubMed DOI PMC

Banach M, Stulc T, Dent R, Toth PP. Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement. Int J Cardiol. 2016;225:184–96. doi: 10.1016/j.ijcard.2016.09.075 PubMed DOI

Moreno Juste A, Gimeno Miguel A, Poblador Plou B, González Rubio F, Aza Pascual-Salcedo MM, Menditto E, et al. Adherence to treatment of hypertension, hypercholesterolaemia and diabetes in an elderly population of a Spanish cohort. Med Clin (Barc). 2019;153(1):1–5. doi: 10.1016/j.medcli.2018.10.023 PubMed DOI

Kim SJ, Kwon OD, Han EB, Lee CM, Oh S-W, Joh H-K, et al. Impact of number of medications and age on adherence to antihypertensive medications: a nationwide population-based study. Medicine (Baltimore). 2019;98(49):e17825. doi: 10.1097/MD.0000000000017825 PubMed DOI PMC

Yourman LC, Cenzer IS, Boscardin WJ, Nguyen BT, Smith AK, Schonberg MA, et al. Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: a meta-analysis. JAMA Intern Med. 2021;181(2):179–85. doi: 10.1001/jamainternmed.2020.6084 PubMed DOI PMC

Goldstein KM, Zullig LL, Bastian LA, Bosworth HB. Statin adherence: does gender matter? Curr Atheroscler Rep. 2016;18(11):63. doi: 10.1007/s11883-016-0619-9 PubMed DOI

Lewey J, Shrank WH, Bowry ADK, Kilabuk E, Brennan TA, Choudhry NK. Gender and racial disparities in adherence to statin therapy: a meta-analysis. Am Heart J. 2013;165(5):665–78, 678.e1. doi: 10.1016/j.ahj.2013.02.011 PubMed DOI

Taibanguay N, Chaiamnuay S, Asavatanabodee P, Narongroeknawin P. Effect of patient education on medication adherence of patients with rheumatoid arthritis: a randomized controlled trial. Patient Prefer Adherence. 2019;13:119–29. doi: 10.2147/PPA.S192008 PubMed DOI PMC

Tan JP, Cheng KKF, Siah RC-J. A systematic review and meta-analysis on the effectiveness of education on medication adherence for patients with hypertension, hyperlipidaemia and diabetes. J Adv Nurs. 2019;75(11):2478–94. doi: 10.1111/jan.14025 PubMed DOI

De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J Clin Pharmacol. 2014;78(4):684–98. doi: 10.1111/bcp.12339 PubMed DOI PMC

Dalli LL, Kilkenny MF, Arnet I, Sanfilippo FM, Cummings DM, Kapral MK, et al. Towards better reporting of the proportion of days covered method in cardiovascular medication adherence: a scoping review and new tool TEN-SPIDERS. Br J Clin Pharmacol. 2022;88(10):4427–42. doi: 10.1111/bcp.15391 PubMed DOI PMC

The effectiveness of a smart-phone application on self-efficacy for adherence to healthy lifestyle behaviors among pregnant women with gestational diabetes mellitus (GDM). 2020. https://trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12620001099910

Banach M, Penson PE. Adherence to statin therapy: it seems we know everything, yet we do nothing. Eur Heart J Open. 2022;2(6):oeac071. doi: 10.1093/ehjopen/oeac071 PubMed DOI PMC

Rosenberg J, Lampridou S, Moores A, Garfield S, Wingfield D, Judah G. A systematic review uncovering modifiable influences on statin adherence. Patient Prefer Adherence. 2025;19:29–48. doi: 10.2147/PPA.S502645 PubMed DOI PMC

Al-Ashwal FY, Sulaiman SAS, Sheikh Ghadzi SM, Kubas MA, Halboup A. Physicians and pharmacists’ clinical knowledge of statin therapy and monitoring parameters, and the barriers to guideline implementation in clinical practice. PLoS One. 2023;18(1):e0280432. doi: 10.1371/journal.pone.0280432 PubMed DOI PMC